Li Fan, Zhang De-Bao, Ma Yue, Song Yang, Duan Xian-Liang
Fan Li, Department of Orthopaedics, Affiliated Hospital of Beihua University, 132011 Jilin, P. R. China.
De-bao Zhang, Department of Orthopaedics, Affiliated Hospital of Beihua University, 132011 Jilin, P. R. China.
Pak J Med Sci. 2024 Mar-Apr;40(4):648-651. doi: 10.12669/pjms.40.4.8536.
To explore the safety and efficacy of metastatic osteosarcoma treatment with combined sintilimab injection and chemotherapy.
We performed a retrospective analysis of 32 patients with metastatic osteosarcoma admitted to the Affiliated Hospital of Beihua University between January 2019 and June 2020. The sample was divided into an observation group, treated with sintilimab injection combined with chemotherapy (n= 16) and a control group, treated with chemotherapy (n = 16). Clinical efficacy and adverse reactions were compared between the two groups.
The overall response rates were 68.75% in the observation group and 31.25% in the control group ( < 0.05). The incidences of adverse reactions were 56.25% in the observation group and 81.25% in the control group. This was not a significant difference. In the observation group, the progression-free survival time was 8.13 ± 2.50 months, and the overall survival time was 22.75 ± 4.95 months. These were both significantly longer than the respective 6.44 ± 1.93 months and 19.69 ± 2.68 months in the control group ( < 0.05).
The treatment of metastatic osteosarcoma with combined sintilimab injection and chemotherapy was found to prolong progression-free survival and overall survival time without increasing the incidence of adverse reactions.
探讨信迪利单抗注射液联合化疗治疗转移性骨肉瘤的安全性和有效性。
对2019年1月至2020年6月期间在北华大学附属医院住院的32例转移性骨肉瘤患者进行回顾性分析。样本分为观察组（n = 16），接受信迪利单抗注射液联合化疗治疗，和对照组（n = 16），接受化疗治疗。比较两组的临床疗效和不良反应。
观察组的总缓解率为68.75%，对照组为31.25%（P<0.05）。观察组不良反应发生率为56.25%，对照组为81.25%。差异无统计学意义。观察组的无进展生存期为8.13±2.50个月，总生存期为22.75±4.95个月。两者均显著长于对照组的6.44±1.93个月和19.69±2.68个月（P<0.05）。
信迪利单抗注射液联合化疗治疗转移性骨肉瘤可延长无进展生存期和总生存期，且不增加不良反应发生率。
